8月26日晚间，诚意药业（603811）发布半年度报告。在关节类药物销售额持续提升的推动下，公司收 入利润延续增长趋势。2025年上半年实现营业收入4.17亿元，同比增长17.11%。利润表现更为突出，上 半年归母净利润及扣非净利润分别达1.12亿元及1.11亿元，同比增长47.03%及54.21%。 大力开发海洋生物制药，氨糖收入同比增48% 盐酸氨基葡萄糖胶囊(下称"氨糖")优秀的销售表现，无疑是报告期内公司经营最突出的亮点之一。继 2024年度关节类药物营收实现同比23.41%增长后，2025年上半年以氨糖为代表的关节类药物营收加速 增长，实现3.39亿元，同比增长47.50%。 氨糖产品良好的销售表现，与公司大力开发海洋生物制药高度相关，一方面体现在产品高品质原材料供 应及良好的临床价值，另一方面则是公司加大市场开拓力度的成果。 除产品自身因素，公司加大市场端投入，对包括氨糖在内的主要产品不断做深做细市场与企业品牌推广 工作，充分实现产品学术、临床治疗和商业模式等多层面合作，成效显著。据披露，至2025年，氨糖销 售已通过全国30个省国采续约，市场份额在此前全国集采9省市超41%的基础上实现持续扩大。 ...

Core Viewpoint - The company, Zhejiang Chengyi Pharmaceutical Co., Ltd., reported a revenue of 714.37 million yuan for the year 2024, reflecting a growth of 6.36% compared to the previous year, with a net profit attributable to shareholders of 200.70 million yuan, an increase of 23.21% [11][12]. Group 1: Company Overview - The company specializes in the research, development, production, and sales of pharmaceutical health products, holding 81 drug production approval numbers and raw material drug registration numbers, with 47 products included in the national medical insurance catalog [8]. - The main products include glucosamine hydrochloride capsules, which are well-received in the market, particularly for treating osteoarthritis, and have achieved a market share of over 41% in nine provinces [6][8]. Group 2: Financial Performance - The company achieved a revenue of 714.37 million yuan, a 6.36% increase year-on-year, and a net profit of 200.70 million yuan, marking a 23.21% growth compared to the previous year [11][12]. - The proposed profit distribution plan includes a cash dividend of 2.50 yuan per 10 shares, amounting to a total distribution of approximately 79.42 million yuan [4]. Group 3: Industry Context - The pharmaceutical manufacturing industry is a significant part of China's economy, driven by increasing healthcare demands due to rising living standards and an aging population [5]. - The company is responding to national initiatives to develop the marine economy by leveraging raw material advantages to create marine biological pharmaceutical products [6].